Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

Eli Lilly says that Zepbound will come out of shortage in the next few days, according to news reports, which suggest it could be a problem for compounded versions. Perhaps that’s how Lilly is spinning it (and far be it for us to imply that Lilly is muddying the waters again).

It’s hopeful news that Lilly’s Zepbound may soon be available again. Whether that production is enough to satisfy demand for tirzepatide injection, which is on the FDA drug shortage list, remains to be seen. Particular dosage forms and dosage strengths of a drug can be available and still not be in sufficient quantities to meet demand. With Mounjaro still largely unavailable, we feel sure FDA will be looking hard at whether Lilly’s renewed Zepbound production is sufficient to meet the extraordinary demand. 

In the meantime, with tirzepatide injection listed as “currently in shortage” on the shortage list, compounding pharmacies can and will continue to receive and fill prescriptions from providers who judge the compounded drug appropriate for a patient.